Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ICU Medical (ICUI)

ICU Medical Q1 2025 revenue rises to $604.7 million; net loss narrows

Positive Impact 3 of 5 earnings Written later

ICU Medical reported first quarter 2025 revenue of $604.7 million, up from $566.7 million a year earlier, and a GAAP net loss of $15.5 million, or $0.63 per diluted share, compared with a $39.5 million loss, or $1.63 per share, in the first quarter of 2024. Adjusted diluted earnings per share rose to $1.72 from $0.96, and CEO Vivek Jain said results were generally in line with company expectations.

Key points

  • Revenue was $604.7 million, compared with $566.7 million in Q1 2024.
  • GAAP net loss was $15.5 million, or $(0.63) per diluted share, versus $39.5 million, or $(1.63) per share, a year earlier.
  • Adjusted diluted EPS was $1.72, compared with $0.96 in Q1 2024; adjusted EBITDA was $99.4 million, versus $78.8 million.
  • GAAP gross margin was 35%, compared with 33% in the prior-year quarter.

The filing

CompanyICU Medical (ICUI)
Form8-K, current report
Filed with the SECMay 8, 2025, 4:08 PM ET
Accession number0000883984-25-000014

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:01 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.